

# KEY INVESTOR INFORMATION

This document provides you with key investor information about this Fund. It is not marketing material. The information is required by law to help you understand the nature and the risks of investing in this Fund. You are advised to read it so you can make an informed decision about whether to invest.

**Magna Biopharma Income Fund (the "Fund"), a sub-fund of Magna Umbrella Fund plc (the "Company")**

**B Accumulating Class Shares ("B Acc Class Shares") (ISIN: IE00B8BFJQ84)**

## OBJECTIVES AND INVESTMENT POLICY

This Fund targets a combination of growing income distributions and capital growth by investing in companies in the Biopharma sector, ie companies that have their primary focus on biotechnology, pharmaceutical and medical device activities.

Its assets are predominately invested in equity securities listed on recognised exchanges issued by companies operating in the Biopharma sector. The Fund may invest up to 20% of its net assets in emerging markets. The Fund may invest in certain derivative instruments (which may result in the Fund being leveraged up to 100% of its NAV) and may also retain significant amounts in cash and other liquid assets in order to cover such positions. Liquid assets may include short rate bonds (rated BB- or higher by Standard & Poor's or its equivalent), time deposits and variable rate notes of investment grade or better.

The allocation of the Fund's assets will be determined by the Investment Manager at its sole discretion and may vary according to market conditions, the Fund is managed with a bottom-up stock picking investment style and is subject to rigorous risk management process.

Any company active in the biotechnology or pharmaceutical industries may be considered for investment, with the exposure of the Fund to any particular security or territory entirely at the discretion of the investment manager. Due to the nature of the sector the majority of the Fund's assets are likely to be invested in US companies.


The Fund is not managed with the intention of outperforming any particular benchmark, though its performance may be measured against a benchmark. Portfolio transaction costs will have a material impact on performance.

This Fund should be considered as a mid- to long-term investment.

This Class is an accumulating class and does not intend to distribute any income arising from the investments that it holds. Other classes in the Fund are either accumulating or distributing.

You may subscribe for or redeem your shares in the Fund on any business day if you tell us before 12 noon the previous day that you want to do so.

## RISK AND REWARD PROFILE



These numbers rate how the Fund may perform. Generally the potential for higher gains also mean a larger risk of losses. The lowest category does not mean a risk free investment.

Historical data, such as is used for calculating this indicator, may not be a reliable indication of the future risk profile of this Fund.

The risk and reward category for this Fund is not guaranteed to remain unchanged, and may shift over time.

This Fund is ranked at 6 because funds of this type have experienced high rises and falls in value in the past.

The fund has the ability to pay the investment management fee and other fees and expenses from capital with the effect that capital may be eroded and that income will be achieved by foregoing the potential for future capital growth.

The following risks may not be fully captured by the risk and reward indicator:

**Liquidity Risk:** Lower liquidity means there may be insufficient buyers or sellers to allow the Fund to sell or buy investments readily.

**Biopharma Sector Risk:** Due to the nature of the Biopharma Sector, companies operating in the sector are subject to higher levels of government regulation than other sectors and as such any changes in regulation can have a material adverse effect on the profitability and performance of investments in their securities. Biopharma Securities may therefore drop sharply in value in response to delays in/denial of regulatory approval and/or setbacks in research and development of

new therapies. In addition, sharp drops in the value of securities may also be caused by the approval of competitive products with superior efficacy and risk profiles or the expiration of patents relating to marketed products.

**Sub-Custodial Risk:** The assets of funds traded in Emerging Markets may require the custodian to entrust safekeeping to sub-custodians which may not provide the same degree of investor protection.

**Taxation Risk:** The laws and practices of certain Emerging countries may not be as well established as those of developed countries and the Company could become subject to taxation laws applied retrospectively and not envisaged at the date investments are made, valued or sold.

**Share Currency Designation Risk:** Changes in the value of the base currency of the Fund relative to the denominated currency of a share class may give rise to a risk for investors.

**Credit Risk:** This refers to the likelihood of the Fund losing money if an issuer is unable to meet its financial obligations or goes bankrupt.

**Counterparty Risk:** The Fund may invest in derivative contracts and may find itself exposed to risk arising from the solvency of its counterparts and from their ability to respect the conditions of these contracts.

**Derivatives Risk:** Derivatives are highly sensitive to changes in the value of the assets they are based on. The impact on the Fund is greater where derivatives are used in an extensive way. The use of derivatives may result in the Fund being leveraged whereby the exposure of the Fund as a result of all positions held by it may exceed its net asset value and may result in gains or losses that are greater than the original amount invested.

For more information on risks, please see the 'Risk Factors' section of the fund's Prospectus.

## CHARGES

One-off charges taken before or after you invest	
Entry charge	None
Exit charge	3.00%
This is the maximum that might be taken out of your money before it is invested or paid out	
Charges taken from the Fund over a year	
Ongoing charge	3.34%
Charges taken from the Fund under certain specific conditions	
Performance fee	10% of the return in excess of the percentage return on the MSCI World Health Care Net EUR Index.

The Investment Management fee and other fees and expenses are charged to capital.

The performance fee for the last financial year was 0%.

The entry and exit charges shown are maximum figures, and in some cases investors may pay less.

The charges you pay are used to pay the costs of running the Fund, including the costs of marketing and distributing it. These charges reduce the potential growth of your investment. You can find out the actual charges from your financial adviser or distributor.


While a switching charge of up to a maximum of 2% of the NAV of the shares of the Fund may apply on switching from the Fund to another fund of the Company, it is not currently intended that any such charge will be applied. Shareholders will be entitled to a minimum of one switch per calendar year free of charge.

Ongoing charges are based on the Fund's financial year to date and then annualised for the period ending 31/12/2016. The ongoing charges may vary from year to year and the Company's annual report will include detail on the exact charges made.

It excludes performance fees and portfolio transaction costs, except costs paid to the Depositary and any entry/exit charge paid to an underlying collective investment scheme, if any.

For more information about charges (including the application of anti-dilution levies), please see 'Fees and Expenses' in the Prospectus, and the Supplement to the Prospectus, which are available on the website of [www.fundinfo.com](http://www.fundinfo.com).

## PAST PERFORMANCE



This chart shows how much the share class increased or decreased in value as a percentage in each year. Performance has been calculated in Euro and takes account of ongoing charges. Past performance is not a reliable guide to future performance.

The Fund was established on 21/12/2012. This Class launched on 05/12/2013.

## PRACTICAL INFORMATION

The Depositary of the Fund is BNY Mellon Trust Company (Ireland) Limited.

The Fund is a sub-fund of Magna Umbrella Fund plc, an umbrella structure comprising different sub-funds. The Fund is subject to tax laws and regulations of Ireland. The tax legislation that applies to the Fund may have an impact on the personal tax position of your investment in the Fund.

You are entitled to switch from one Fund of the Company to another or from one share class to another within the same sub-fund. Information on how to switch is in the section 'The Shares' in the Prospectus.

The assets and liabilities of the Fund are segregated from other funds in the Company, subject to the provisions of Irish law.

The Prospectus and periodic reports are in the name of the Company and copies are available free of charge from the Administrator and the Share Distributor. The Prospectus, KIIDs, share prices, annual and half-yearly reports and shareholder notices are available in English and German on the website of [www.fundinfo.com](http://www.fundinfo.com).

Magna Umbrella Fund plc may be held liable solely on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the Prospectus for the Fund.

The NAV of the B Acc Class Shares will be calculated in Euro and a currency conversion calculation effected to obtain the NAV per Share in Canadian Dollars, Australian Dollars, Sterling and US Dollars. The NAV per Share will be published daily on the website of [www.fundinfo.com](http://www.fundinfo.com).

Available ISINs for this Class are Sterling IE00BGH1KD00, US Dollar IE00BGH1KF24 and Australian Dollar IE00BKJ8RK39.

Details of the up-to-date remuneration policy, including, but not limited to, a description of how remuneration and benefits are calculated, the identity of persons responsible for awarding the remuneration and benefits including the composition of the remuneration committee, if any, are available at [www.charlemagne-capital.com/](http://www.charlemagne-capital.com/) and a paper copy of the remuneration is available on request from the Company.